Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7687607> ?p ?o }
Showing triples 1 to 30 of
30
with 100 triples per page.
- Q7687607 subject Q8255706.
- Q7687607 abstract "Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche.Two phase II trials reported it was effective and well tolerated.Of the eight planned phase III clinical trials of weekly taspoglutide (four against exenatide, sitagliptin, insulin glargine, and pioglitazone), at least five were active in 2009. Preliminary results in early 2010 were favourable. (At least one of the eight planned phase III trials had not started recruiting by end 2009.)In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects.As of May 2013 no new trials had been registered.".
- Q7687607 atcPrefix "none".
- Q7687607 casNumber "275371-94-3".
- Q7687607 fdaUniiCode "2PHK27IP3B".
- Q7687607 wikiPageWikiLink Q111546.
- Q7687607 wikiPageWikiLink Q12140.
- Q7687607 wikiPageWikiLink Q1420402.
- Q7687607 wikiPageWikiLink Q2035485.
- Q7687607 wikiPageWikiLink Q212646.
- Q7687607 wikiPageWikiLink Q2526479.
- Q7687607 wikiPageWikiLink Q3025883.
- Q7687607 wikiPageWikiLink Q417317.
- Q7687607 wikiPageWikiLink Q417762.
- Q7687607 wikiPageWikiLink Q417765.
- Q7687607 wikiPageWikiLink Q419770.
- Q7687607 wikiPageWikiLink Q419832.
- Q7687607 wikiPageWikiLink Q4712362.
- Q7687607 wikiPageWikiLink Q5572286.
- Q7687607 wikiPageWikiLink Q8255706.
- Q7687607 atcPrefix "none".
- Q7687607 casNumber "275371".
- Q7687607 unii "2".
- Q7687607 type ChemicalSubstance.
- Q7687607 type Drug.
- Q7687607 type ChemicalObject.
- Q7687607 type Thing.
- Q7687607 type Q8386.
- Q7687607 comment "Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche.Two phase II trials reported it was effective and well tolerated.Of the eight planned phase III clinical trials of weekly taspoglutide (four against exenatide, sitagliptin, insulin glargine, and pioglitazone), at least five were active in 2009. Preliminary results in early 2010 were favourable.".
- Q7687607 label "Taspoglutide".